# Fat Soluble Vitamins in Adult Cystic Fibrosis Guideline

## 1. Introduction

This guideline is intended for use by all prescribing members of the Adult Cystic Fibrosis (CF) multidisciplinary team (MDT) to optimise fat soluble vitamin supplementation.

# <u>2. Scope</u>

People with cystic fibrosis, particularly those with pancreatic insufficiency, are at risk of fat soluble vitamin deficiencies. A significant correlation between vitamin A and E deficiency and pancreatic insufficiency has been reported at the time of diagnosis however no correlation is reported between pancreatic status and vitamin D deficiency.

Most people with CF who are pancreatic insufficient will require supplementation with the fat soluble vitamins A,D, E and K.

Most people with CF who are pancreatic sufficient require supplementation with vitamin D and some may require additional vitamin A, vitamin E and/or vitamin K.

- Vitamin A has an important role in the eye, skin, respiratory and immune systems.
- Vitamin D is fundamental for calcium absorption from the gut and subsequently important for bone health. Without adequate vitamin D, only 15-20% of dietary calcium and 60% of phosphorus are absorbed when Vitamin D replete 30-50% of calcium is absorbed (Holick et al, 2011). In addition to bone health, there is increasing recognition and interest in the non-skeletal roles of vitamin D in respiratory function, muscle function, diabetes and cardiovascular diease.
- Vitamin E is an important antioxidant. It reduces the effects of free radicals produced by infection and chronic inflammation, therefore helping to protect cell membranes from oxidative damage.
- Vitamin K is vital for normal blood coagulation and important for good bone health. Interest has been shown, more recently, in its role in energy metabolism and inflammation which may be of importance in CF.

This guideline includes: the recommended levels for each fat soluble vitamin; recommended maintenance supplementation doses; how to escalate doses if serum levels are low; and when to refer for discussion with the CF MDT.

## 3. Recommendations, Standards and Procedural Statements

## 3.1 Assessment

Vitamin A, D and E, along with eGFR, C Reactive Protein (CRP), adjusted calcium, alkaline phosphatase and phosphorus are checked routinely for each patient once a year at their annual review and following treatment adjustments.

Consider measuring PTH if deemed to be at risk of Cystic Fibrosis bone disease (e.g. previously identified bone disease or chronically low vitamin D, low phosphate, low body weight).

Acute phase response to infection (indicated by a raised CRP or an acute exacerbation of CF) can lead to falsely low vitamin A and vitamin D levels. If CRP is raised at the time of checking vitamin levels, recheck when CRP has normalised before commencing additional supplementation.

If the level reported for each fat soluble vitamin is lower than the recommended range, check the following and if additional supplementation is still required follow section 2.4

- 1. Check adherence to maintenance vitamin preparation(s) the patient is prescribed and confirm the strength and the number of tablets / capsules
- 2. Check for any over the counter (OTC) preparations or supplements
- 3. Check the fat soluble vitamins are taken with fat containing food to maximise absorption
- 4. If pancreatic insufficient, check fat soluble vitamins are taken alongside pancreatic enzymes to maximise absorption

### **3.2 Recommended Levels**

	Recommended level	Adult recommended daily dosage
Vitamin A (if >19yrs)	1.1 – 2.8 µmol/L	1500 – 10,000 international units
Vitamin A (13 – 19yrs)	0.9 - 2.5 µmol/L	1500 – 10,000 international units
Vitamin D*	>50 nmol/L*	400 – 5000 international units (10 - 125 micrograms)
Vitamin E (if >19yrs)	12 – 42 µmol/L	150 – 500 international units
Vitamin E (13 – 19 yrs)	14 – 23 µmol/L	150 – 500 international units
Vitamin K	Not routinely monitored	5 – 10mg

\*Risk of toxicity increased when serum colecaciferol concentrations exceed 220 nmol/L

### 3.3 Vitamin Preparations

### Daily Maintenance Vitamins:

Pancreatic insufficient

Preparation	Dose	Constituents	Comments
1 <sup>st</sup> line:			
Paravit CF Capsules	2 capsules once a day	Per 2 capsule dose: vitamin A 8,000 units vitamin D 3000 units, vitamin E 300 units, vitamin K 10mg	

Paravit CF Liquid	0.5ml once a day	Per 0.5ml dose: vitamin A 8,000 units, vitamin D 3000 units, vitamin E 300 units, vitamin K 10mg	Suitable for vegetarians
Other available preparati	ons:		
DEKAs Essential capsules	1 capsule once a day	Per capsule Vitamin A 2000 units (1500 units as beta- carotene and 500 units as retinol palmitate) Vitamin D3 2000 units Vitamin E 150 units Vitamin K 1000 micrograms	See pregnancy information below
Vitamin A and D (4000units / 400 units) capsules	1-3 capsules once a day	Per capsule: vitamin A 4000 units vitamin D 400 units	
Vitamin E (75 units, 200 units, 400 units) capsules	150 – 500 units once a day		
Vitamin K (10mg) tablet	5 – 10mg once a day		Often difficult to source and expensive

## For Further Supplementation

Preparation	Dose
Vitamin D	
Colecalciferol 20,000 unit capsules	See 3.4

### **Pancreatic Sufficient**

Please refer to Leicestershire Medicines Strategy group (LLR) Diagnosis and Management of Vitamin D Deficiency (Last updated December 2022)

## Vitamin-d-guide-1.pdf (areaprescribingcommitteeleicesterleicestershirerutland.nhs.uk)

### Cautions / Contraindications / Interactions

For vitamin K containing supplements, discuss with CF MDT if also prescribed anticoagulants

For vitamin A containing supplements, potential interaction with retinoids and bexarotene leading to toxicity, discuss with CF MDT.

### Pregnancy and Breastfeeding

See Trust CF pregnancy and breastfeeding drug monographs

For vitamin A containing supplements, maximum daily dose in pregnancy 10,000 units per day

For patients who may be at risk of exceeding 10,000 units of vitamin A per day, e.g. through diet or additional supplementation, consider switching to DEKAs Essential capsules.

Most of the vitamin A in DEKAs is given as ß-carotene, which is a precursor to vitamin A and is converted by the body to vitamin A as needed. Therefore, there is no risk of hypervitaminosis A.

#### Renal Impairment

If eGFR less than 30mls/min/1.73m<sup>2</sup> discuss with MDT

#### Raised CRP

If CRP level is raised at the time of checking vitamin D wait three months or until CRP is normal and check level again. A raised CRP can lead to a falsely low vitamin D. If both CRP and PTH level are raised this would indicate vitamin D deficiency and supplementation required.

### 3.4 Dose Adjustment if Vitamin Levels Lower than Recommended Range:

	Dose Adjustment	Monitoring	
Vitamin A <1.1 µmol/L	If taking full dose Paravit CF, discuss with CF MDT Check CRP, zinc and retinol binding protein	After adjusting supplementation, repeat levels	
	If taking vitamin A and D, increase up to 3 capsules once a day. If remains low, discuss with CF MDT Check CRP, zinc level and retinol binding protein	at 3 months	
Vitamin E <12 µmol/L if >19 years <14 µmol/L if 13 – 19 years	If taking full dose Paravit CF, discuss with CF MDT	After adjusting	
	If taking vitamin E, increase up to 500 units daily. If remains low, discuss with CF MDT	supplementation, repeat levels at 3 months	
Vitamin D <50nmol/l	Supplement with a 'booster' of 300,000 units of Vitamin D3 orally in divided doses over 5- 10 weeks alongside maintenance dose e.g.	Follow monitoring algorithm - Appendix A	

Refer to 3.1 before adjusting vitamin therapy

Fat Soluble Vitamins in Adult Cystic Fibrosis Guideline Page 4 of 7 v2 approved by Policy and Guideline Committee on 18 August 2023 Trust Ref: B36/2021

and Guideline Committee on 18 August 2023 Trust Ref: B36/2021

Date of Next Review: Sept 2026

NB: Paper copies of this document may not be most recent version. The definitive version is held on InSite in the Policies and Guidelines Library

60,000 units per week for 5 weeks 20,000 units twice a week for 7 weeks	
On completion of booster dose, continue maintenance treatment	

### 3.5 Dose Adjustment if Vitamin Levels Higher than Recommended Range

- Check for OTC supplements
- Check for other nutritional preparations
- Refer to CF MDT for discussion

### 4. Education and Training

None

### 5. Monitoring and Audit Criteria

All guidelines should include key performance indicators or audit criteria for auditing compliance,

if this template is being used for associated documents (such as procedures or processes) that support a Policy then this section is not required as all audit and monitoring arrangements will be documented in section 8 of the Policy.

Key Performance Indicator	Method of Assessment	Frequency	Lead
Appropriate prescribing of fat soluble vitamins in adult patients with CF	Audit prescribing practice within CF MDT	Bi-annually	Pharmacist and Dietitian

## 6. Supporting Documents and Key References

Guidelines for Use of Pancreatic Enzyme Replacement Therapy Trust ref: B10/2019

Nutritional Management of Cystic Fibrosis, Cystic Fibrosis Trust, Second Edition Sept 2016

Nutrition guidelines for Cystic Fibrosis in Austrialia and Newzeland, August 2017


Holick, MF, Binkley, NC, Bischoff-Ferrari, HA, Gordon, CM, Hanley, DA, Heaney, RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96, 1911-1930 (2011).

### 7. Key Words

Cystic Fibrosis, fat soluble vitamins, vitamin A, vitamin D, vitamin E, vitamin K

## Oral Vitamin D supplementation guide if 25(OH)D level <50nmol/L for pancreatic insufficient cystic fibrosis adult patients

Before escalating treatment of vitamin D deficiency, check adherence to current supplementation/Pancreatic Enzyme Replacement Therapy (PERT) and at every dose adjustment



NB: Paper copies of this document may not be most recent version. The definitive version is held on InSite in the Policies and Guidelines Library

#### This line signifies the end of the document

This table is used to track the development and approval and dissemination of the document and any changes made on revised / reviewed versions

	DEVELO	PMENT AND APPRO	AL RECO	ORD FOR THIS	S DOCUMENT	
Author / Lead Officer:	Jessica ( Lydia Ste	ca Gadsby Stevens		<b>Job Title:</b> Advanced Specialist Pharmacist Senior Specialist Dietitian		
Reviewed by:		Jessica Gadsby, Advanced Specialist Pharmacist Lydia Stevens, Senior Specialist Dietitian				
Approved by:	Policy a	nd Guideline Committe	ee Date Approved: September 2021 (v1); 18.8.23 9v2)			
REVIEW RECORD						
Date	lssue Number	Reviewed By	Description Of Changes (If Any)			
10/07/23		Jessica Gadsby Lydia Stevens	Amendment regarding measuring PTH Paravit CF vitamin A content updated Link to local vitamin D guideline updated Appendix B vitamin D monitoring proforma removed			
		DISTRIBL		CORD:		
Date	Name			Dept		Received